DENTSPLY SIRONA (NASDAQ: XRAY) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Earnings and Valuation

This table compares DENTSPLY SIRONA and AtriCure’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
DENTSPLY SIRONA $3.84 billion 3.55 $823.80 million ($3.47) -17.10
AtriCure $166.00 million 4.35 -$19.62 million ($1.01) -20.83

DENTSPLY SIRONA has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for DENTSPLY SIRONA and AtriCure, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DENTSPLY SIRONA 1 2 7 0 2.60
AtriCure 0 1 6 0 2.86

DENTSPLY SIRONA presently has a consensus price target of $65.78, indicating a potential upside of 10.85%. AtriCure has a consensus price target of $24.83, indicating a potential upside of 18.03%. Given AtriCure’s stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than DENTSPLY SIRONA.

Volatility & Risk

DENTSPLY SIRONA has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

94.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 82.1% of AtriCure shares are owned by institutional investors. 2.0% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 10.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. AtriCure does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.

Profitability

This table compares DENTSPLY SIRONA and AtriCure’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DENTSPLY SIRONA -20.57% 7.24% 5.02%
AtriCure -19.56% -19.56% -11.91%

Summary

DENTSPLY SIRONA beats AtriCure on 9 of the 15 factors compared between the two stocks.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

About AtriCure

AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA).

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.